Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemoradiation for resectable, non-metastasized ductal adenocarcinoma of the pancreas
DRKS00003893Phase 3Not yet recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Planned start Jan 2014; status: not yet recruiting.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on DRKS00003893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003893.